San Francisco Bay Area biotech stories.
Friday, September 7, 2012
Jazz Pharma to sell women's health business for $95M
Jazz Pharmaceuticals will sell its women's heath business to specialty pharmaceutical company Meda for $95 million in cash.
Jazz, which has an office in Palo Alto (NASDAQ:JAZZ) said in the release that the sale involves six products: Elestrin, Gastrocrom, Natelle One, AVC, Gesticare DHA and Urelle.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)